Fierce Biotech
Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to $5.2 billion.